Stanford’s proteomic analysis spinout has lifted its funding haul beyond $100m with a round set to drive new hires and technology development.
Nautilus Biotechnology, a US-based proteomic analysis technology business exploiting Stanford University research, has secured $76m in an oversubscribed series B round featuring venture capital firm Andreessen Horowitz.
The round was led by Vulcan Capital, the investment office of software producer Microsoft’s co-founder Paul Allen, with participation from Bezos Expeditions, Perceptive Advisors, Defy Partners, AME Cloud Ventures, Bolt and Madrona Venture Group.
Nautilus completed the transaction on May 18, 2020 before making an official announcement on Thursday.
Founded in 2016, Nautilus Biotechnology is building a proteomic analysis platform to support drug discovery by underpinning deeper knowledge of how fundamental biological proteins are structured.
The platform appraises proteins at single-molecule resolution in order to accelerate biomedical projects, improving the likelihood of success.
Nautilus was co-founded by Parag Mallick, associate professor of radiology at Stanford University and a member of Stanford-based interdisciplinary bioscience institute BioX.
The series B cash is expected to fund the recruitment of more scientists and engineers as Nautilus seeks to drive the development of its platform.
Nautilus said it had now raised more than $100m in funding, having previously completed a $27.2m round featuring undisclosed investors in 2018, according to a regulatory filing.
AME Cloud Ventures, Andreessen Horowitz, Bolt and Madrona Venture Group all backed the series B round as existing investors.
